中外医疗
中外醫療
중외의료
CHINA FOREIGN MEDICAL TREATMENT
2015年
8期
177-179
,共3页
徐悦涛%张虹%张豪荣%程剑
徐悅濤%張虹%張豪榮%程劍
서열도%장홍%장호영%정검
化疗后白细胞减少症%足三里注射%参麦注射液%重组人粒细胞集落刺激因子
化療後白細胞減少癥%足三裏註射%參麥註射液%重組人粒細胞集落刺激因子
화료후백세포감소증%족삼리주사%삼맥주사액%중조인립세포집락자격인자
Leukopenia after chemotherapy%Zusanli acupoint%Shenmaiinjection%Recombinant human granulocyte colony stimulating factor lating factor
目的：研究参麦注射液足三里注射联合重组人粒细胞集落刺激因子治疗化疗后白细胞减少症的疗效。方法将化疗所致白细胞减少症患者随机分为3组（治疗组1、治疗组2和对照组）。对照组给予重组人粒细胞集落刺激因子150 ug皮下注射，第一天注射一次，治疗组2在对照组的基础上，给予参麦注射液40 mL静滴，1次/d，连续3 d。治疗组1在对照组的基础上，加以参麦注射液足三里注射，每穴2 mL，第一天注射一次。分别观察治疗后第3天、第8天、第15天的白细胞指数。结果三组患者临床疗效比较：治疗组1、治疗组2、对照组，在第3天总有效果率分别为96.7%，90.0%，86.7%；在第8天分别为93.3%，80.0%，73.3%，在第15天分别为：83.3%，56.7%，43.3%。治疗组1和治疗组2的不良反应都小于对照组。结论参麦注射液足三里注射联合重组人粒细胞集落刺激因子治疗化疗后白细胞减少症能提高疗效，减少不良反应，并且参麦注射液足三里注射疗效好于静滴。
目的：研究參麥註射液足三裏註射聯閤重組人粒細胞集落刺激因子治療化療後白細胞減少癥的療效。方法將化療所緻白細胞減少癥患者隨機分為3組（治療組1、治療組2和對照組）。對照組給予重組人粒細胞集落刺激因子150 ug皮下註射，第一天註射一次，治療組2在對照組的基礎上，給予參麥註射液40 mL靜滴，1次/d，連續3 d。治療組1在對照組的基礎上，加以參麥註射液足三裏註射，每穴2 mL，第一天註射一次。分彆觀察治療後第3天、第8天、第15天的白細胞指數。結果三組患者臨床療效比較：治療組1、治療組2、對照組，在第3天總有效果率分彆為96.7%，90.0%，86.7%；在第8天分彆為93.3%，80.0%，73.3%，在第15天分彆為：83.3%，56.7%，43.3%。治療組1和治療組2的不良反應都小于對照組。結論參麥註射液足三裏註射聯閤重組人粒細胞集落刺激因子治療化療後白細胞減少癥能提高療效，減少不良反應，併且參麥註射液足三裏註射療效好于靜滴。
목적：연구삼맥주사액족삼리주사연합중조인립세포집락자격인자치료화료후백세포감소증적료효。방법장화료소치백세포감소증환자수궤분위3조（치료조1、치료조2화대조조）。대조조급여중조인립세포집락자격인자150 ug피하주사，제일천주사일차，치료조2재대조조적기출상，급여삼맥주사액40 mL정적，1차/d，련속3 d。치료조1재대조조적기출상，가이삼맥주사액족삼리주사，매혈2 mL，제일천주사일차。분별관찰치료후제3천、제8천、제15천적백세포지수。결과삼조환자림상료효비교：치료조1、치료조2、대조조，재제3천총유효과솔분별위96.7%，90.0%，86.7%；재제8천분별위93.3%，80.0%，73.3%，재제15천분별위：83.3%，56.7%，43.3%。치료조1화치료조2적불량반응도소우대조조。결론삼맥주사액족삼리주사연합중조인립세포집락자격인자치료화료후백세포감소증능제고료효，감소불량반응，병차삼맥주사액족삼리주사료효호우정적。
Objective To observe the therapeutic effectof leukopenia after chemotherapy treated withzusanli acupointinjection by shenmaiinjectionandsubcutaneous injection by recombinant human granulocyte colony stimulating factor. Methods 90 cases of leukopenia after chemotherapy were randomly divided into two treatment group and one control groups. The treatment -1 group was treated with zusanli acupointinjection by shenmai injection and subcutaneous injection by recombinant human granulocyte colony stimulating factor. The control group was treated with subcutaneous injection by recombinant human granulocyte colony stimulating factor. The treatment-2 group was treated with Intravenous drip by zusanli acupoint and recombinant human granulocyte colony stimulating factor. After 3、8、15 days, observe the therapeutic effect. Results The total effective rate was 96.7%in the treatment-1 group, 90.0% in the treatment group-2,and 86.7% in the control group in 3 days after treatment; it was 93.3%in the treatment-1 group, it was 80.0%in the control treatment-2,and it was 73.3%in the control group in 8 days after treatment;it was 83.3 in the treatment group-1, it was 56.7% in the treatment l group-2,and it was 43.3% in the control group in 15 days after treatment. The adverse reaction rate of the treatment-1 group and the treatment group-2 is lower than the control group. Conclusion Zusanli acupointinjection by shenmai injection and subcutaneous injection by recombinant human granulocyte colony stimulating factor can improve therapeutic effect and reduce adverse reactions when treat leukopenia after chemotherapy.
